Below are the most recent publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Profiles.
-
Zweegman S, Facon T, Hungria V, Bahlis NJ, Venner CP, Braunstein M, Pour L, Marti J, Basu S, Cohen YC, Matsumoto M, Suzuki K, Hulin C, Grosicki S, Legiec W, Beksac M, Maiolino A, Takamatsu H, Perrot A, Turgut M, Liu W, Wang J, van Brummelen E, Krevvata M, Lopez-Masi L, Carey J, Borgsten F, Rowe M, Carson R, Usmani SZ. Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS. Blood Adv. 2026 08 25; 10(16):5594-5606.
-
Tan CR, Gordan L, Richter J, DiLeo R, Mewawalla P, Larson S, Davies F, Oveisi D, Gupta-Werner N, Medhekar R, Yin X, Cortoos A, Armoon M, Thompson-Leduc P, Rahman A, Tardif-Samson A, Vanden Eynde C, Reitan J, Milkovich G, Bubalo J, Forman A, Bryan B, Sborov D, Kaila S, Usmani S. Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma. Future Oncol. 2026 Aug; 22(18):2169-2177.
-
Bahlis N, Facon T, San-Miguel J, Usmani SZ, Dimopoulos MA, Moreau P, Zweegman S, Perrot A, Manier S, Chari A, Raje N, Orlowski RZ, Goldschmidt H, Basu S, Hulin C, Weisel K, Mohty M, Leleu X, Plesner T, Jakubowiak A, Cook G, Quach H, Venner CP, Cavo M, Ngo M, Bolyard K, Carson R, Borgsten F, Mateos MV, Kumar SK. Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE. Blood Adv. 2026 07 14; 10(13):4541-4550.
-
Mina R, Terpos E, Cani L, Nooka A, Trudel S, Voorhees P, Mian H, Dhakal B, Usmani S, Richter J, Popat R, Mateos MV, Lonial S. Belantamab Mafodotin for Patients With Multiple Myeloma: Clinical Development and Practical Strategies for Dose Optimization and Toxicity Management. Clin Lymphoma Myeloma Leuk. 2026 Sep; 26(9):609-622.
-
Roboz GJ, Zeidan AM, Mannis GN, Montesinos P, Arnan M, Savona MR, Odenike O, McCloskey JK, Amin HV, Fathi AT, Bernal Del Castillo T, Rodríguez-Macías G, Liesveld JL, Im AP, Cerny J, Gentile TC, Oganesian A, Chan D, Wan Y, Dijkstra M, Keer HN, Griffiths EA, DiNardo CD. All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia. N Engl J Med. 2026 Jun 04; 394(21):2107-2116.
-
Garrido-Castro AC, Graham N, Li KX, Bi L, Crowdis J, Bi K, Park J, Pastorello R, Li Y, Gupta H, Kuntz T, Petry R, Pasquina LW, Patel A, Lange P, DiLullo M, Attaya V, Frey AM, Childress MA, Wesolowski R, Sinclair N, Sinclair S, Lo S, Tung N, Faggen M, Kaufman PA, Block CC, Walsh J, Toke M, Chen W, Wucherpfennig KW, Tian Y, Williams AJ, Mukhopadhyay S, Dasgupta T, Schnitt S, Cherniack AD, Barroso R, Ligibel J, Lin NU, Mittendorf EA, Tayob N, Van Allen E, Tolaney SM. Carboplatin with or without nivolumab in metastatic triple-negative breast cancer: a randomized phase II trial. Nat Commun. 2026 May 16; 17(1).
-
Maclachlan KH, Tan CR, Shekarkhand T, Rueda C, Derkach A, Hashmi H, Hassoun H, Shah UA, Hultcrantz M, Lesokhin AM, Mailankody S, Maura F, Merz M, Firestone R, Jurgens EM, Miller KC, Rajeeve S, Giralt S, Shah GL, Scordo M, Landau HJ, Zhang Y, Cimera R, Arcila ME, Korde N, Usmani SZ. IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM. Blood Adv. 2026 Apr 28; 10(8):2616-2625.
-
Suzuki K, Matsumoto M, Takamatsu H, Kosugi H, Kondo T, Fujisaki T, Facon T, Zweegman S, Ito M, Sakai C, Kanai S, Nakatogawa T, Rowe M, Carson R, Usmani SZ. Daratumumab plus VRd in Japanese transplant-ineligible/deferred NDMM patients: Japanese subgroup of the CEPHEUS trial. Int J Hematol. 2026 Jul; 124(1):104-113.
-
Porter RL, Zhou Y, Eskndir N, Hayes M, Polak M, Lee EK, Krasner C, Campos S, Wright AA, Liu JF, Stover EH, Sawyer H, Xiong N, Pfaff KL, Rodig SJ, Tayob N, Zweizig S, John V, Veneris J, Matulonis UA, Konstantinopoulos PA. Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial. Nat Commun. 2026 Mar 26; 17(1).
-
Yu JX, Suh JM, Popova KD, Garcia K, Joshi T, Culbertson B, Spinelli JB, Subramanyam V, Lou K, Charbonneau T, Shokat KM, Weissman J, Goodarzi H. The GENEVA platform models tumor mosaicism to reveal variations of responses to KRAS inhibitors and identify improved drug combinations. Nat Cancer. 2026 Mar; 7(3):522-537.